RNLXD (Renalytix) Valuation Rank


RNLXD Renalytix PLC RNLXD
46 GF Score
Price $4.11
GF Value $8.93
! 3 Warning Signs
View Full Analysis

What is Renalytix Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Renalytix Valuation Rank Related Terms

RNLXD
46GF Score
Renalytix PLC RNLXD
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Renalytix (RNLXD) Overvalued in 2026?

Based on GuruFocus' analysis, Renalytix stock appears to be undervalued. The current stock price of $4.11 is trading 54% below its estimated GF Value™ of $8.93.

Key valuation signals for RNLXD:

  • Valuation Rank:
  • GF Value™: $8.93 vs. price of $4.11 (54% below fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the RNLXD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renalytix Business Description

Other Exchanges RENXF:USARENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
46GF Score

Get the complete analysis for RNLXD

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.11
Price
$8.93
GF Value